165 related articles for article (PubMed ID: 38233570)
1. Immune profiling of patients with extranodal natural killer/T cell lymphoma treated with daratumumab.
Qing M; Zhou T; Perova T; Abraham Y; Sweeney C; Krevvata M; Zhang X; Qi M; Gao G; Kim TM; Yao M; Cho SG; Eom HS; Lim ST; Yeh SP; Kwong YL; Yoon DH; Kim JS; Kim WS; Zhou L; Attar R; Verona RI
Ann Hematol; 2024 Jun; 103(6):1989-2001. PubMed ID: 38233570
[TBL] [Abstract][Full Text] [Related]
2. Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study.
Huang H; Zhu J; Yao M; Kim TM; Yoon DH; Cho SG; Eom HS; Lim ST; Yeh SP; Song Y; Kwong YL; Kim JS; Jin J; Shi Y; Kim H; Qing M; Zhou T; Gao G; Dong Z; Qi M; Kim WS
J Hematol Oncol; 2021 Feb; 14(1):25. PubMed ID: 33588922
[TBL] [Abstract][Full Text] [Related]
3. High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.
Adams HC; Stevenaert F; Krejcik J; Van der Borght K; Smets T; Bald J; Abraham Y; Ceulemans H; Chiu C; Vanhoof G; Usmani SZ; Plesner T; Lonial S; Nijhof I; Lokhorst HM; Mutis T; van de Donk NWCJ; Sasser AK; Casneuf T
Cytometry A; 2019 Mar; 95(3):279-289. PubMed ID: 30536810
[TBL] [Abstract][Full Text] [Related]
4. Updating targets for natural killer/T-cell lymphoma immunotherapy.
Xue W; Zhang M
Cancer Biol Med; 2021 Feb; 18(1):52-62. PubMed ID: 33628584
[TBL] [Abstract][Full Text] [Related]
5. Analysis of latent T-cell epitopes in Epstein-Barr virus isolated from extranodal nasal-type natural killer/T-cell lymphoma in Taiwanese population.
Chou CC; Tsao CF; Liao CK; You HL; Wang MC; Huang WT
Exp Mol Pathol; 2021 Feb; 118():104577. PubMed ID: 33242451
[TBL] [Abstract][Full Text] [Related]
6. Genome-Wide Analysis of Epstein-Barr Virus Isolated from Extranodal NK/T-Cell Lymphoma, Nasal Type.
Lin N; Ku W; Song Y; Zhu J; Lu Z
Oncologist; 2019 Sep; 24(9):e905-e913. PubMed ID: 30940744
[TBL] [Abstract][Full Text] [Related]
7. Determinants of response to daratumumab in Epstein-Barr virus-positive natural killer and T-cell lymphoma.
Mustafa N; Nee AHF; Chooi JY; Toh SHM; Chung TH; Selvarajan V; Fan S; Ng SB; Poon M; Chan E; Lee J; Chee YL; Jeyasekharan AD; Zhou L; Yang J; Chng WJ
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34215687
[TBL] [Abstract][Full Text] [Related]
8. The CD38
Sarkar S; Chauhan SKS; Daly J; Natoni A; Fairfield H; Henderson R; Nolan E; Swan D; Hu J; Reagan MR; O'Dwyer M
Cancer Immunol Immunother; 2020 Mar; 69(3):421-434. PubMed ID: 31919623
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the humoral immune response to the EBV proteome in extranodal NK/T-cell lymphoma.
Liu Z; Sarathkumara YD; Chan JKC; Kwong YL; Lam TH; Ip DKM; Chiu BC; Xu J; Su YC; Proietti C; Cooper MM; Yu KJ; Bassig B; Liang R; Hu W; Ji BT; Coghill AE; Pfeiffer RM; Hildesheim A; Rothman N; Doolan DL; Lan Q
Sci Rep; 2021 Dec; 11(1):23664. PubMed ID: 34880297
[TBL] [Abstract][Full Text] [Related]
10. CD56-Negative Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Study in 443 Patients Treated by Chemotherapy With or Without Asparaginase.
Yang J; Li P; Piao Y; Liu X; Wei L; Sang W; Zhang L; Wang L
Front Immunol; 2022; 13():829366. PubMed ID: 35371002
[TBL] [Abstract][Full Text] [Related]
11. SLC1A1 mediated glutamine addiction and contributed to natural killer T-cell lymphoma progression with immunotherapeutic potential.
Xiong J; Wang N; Zhong HJ; Cui BW; Cheng S; Sun R; Chen JY; Xu PP; Cai G; Wang L; Sun XJ; Huang JY; Zhao WL
EBioMedicine; 2021 Oct; 72():103614. PubMed ID: 34628354
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.
Bi XW; Wang H; Zhang WW; Wang JH; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Zhang YJ; Wang L
J Hematol Oncol; 2016 Oct; 9(1):109. PubMed ID: 27737703
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD38 Therapy with Daratumumab for Relapsed/Refractory CD20-Negative Diffuse Large B-Cell Lymphoma.
Vockova P; Svaton M; Karolova J; Pokorna E; Vokurka M; Klener P
Folia Biol (Praha); 2020; 66(1):17-23. PubMed ID: 32512655
[TBL] [Abstract][Full Text] [Related]
14. Genomic and transcriptomic landscapes of Epstein-Barr virus in extranodal natural killer T-cell lymphoma.
Peng RJ; Han BW; Cai QQ; Zuo XY; Xia T; Chen JR; Feng LN; Lim JQ; Chen SW; Zeng MS; Guo YM; Li B; Xia XJ; Xia Y; Laurensia Y; Chia BKH; Huang HQ; Young KH; Lim ST; Ong CK; Zeng YX; Bei JX
Leukemia; 2019 Jun; 33(6):1451-1462. PubMed ID: 30546078
[TBL] [Abstract][Full Text] [Related]
15. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.
Krejcik J; Casneuf T; Nijhof IS; Verbist B; Bald J; Plesner T; Syed K; Liu K; van de Donk NW; Weiss BM; Ahmadi T; Lokhorst HM; Mutis T; Sasser AK
Blood; 2016 Jul; 128(3):384-94. PubMed ID: 27222480
[TBL] [Abstract][Full Text] [Related]
16. Single-Cell Analysis Reveals Malignant Cells Reshape the Cellular Landscape and Foster an Immunosuppressive Microenvironment of Extranodal NK/T-Cell Lymphoma.
Li YQ; Luo CL; Jiang JX; He S; Liu Y; Yan WX; Xia Y; Cui Q; Huang Y; Lim JQ; Huang D; Hussein IN; Gao Y; Lin GW; Ling YH; Ma D; Zhang YT; Chan JY; Wei PP; Wang XX; Cheng CL; Xiong J; Zhao WL; Ong CK; Lim ST; Huang HQ; Peng RJ; Bei JX
Adv Sci (Weinh); 2023 Dec; 10(36):e2303913. PubMed ID: 37949673
[TBL] [Abstract][Full Text] [Related]
17. T-cell dysfunction in natural killer/T-cell lymphoma.
Feng X; Meng M; Li H; Gao Y; Song W; Di R; Li Z; Zhang X; Zhang M
Oncoimmunology; 2023; 12(1):2212532. PubMed ID: 37250921
[TBL] [Abstract][Full Text] [Related]
18. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations.
Lin GW; Xu C; Chen K; Huang HQ; Chen J; Song B; Chan JKC; Li W; Liu W; Shih LY; Chuang WY; Kim WS; Tan W; Peng RJ; Laurensia Y; Cheah DMZ; Huang D; Cheng CL; Su YJ; Tan SY; Ng SB; Tang TPL; Han K; Wang VY; Jia WH; Pei Z; Li YJ; Gao S; Shi Y; Hu Z; Zhang F; Zhang B; Zeng YX; Shen H; He L; Ong CK; Lim ST; Chanock S; Kwong YL; Lin D; Rothman N; Khor CC; Lan Q; Bei JX;
Lancet Oncol; 2020 Feb; 21(2):306-316. PubMed ID: 31879220
[TBL] [Abstract][Full Text] [Related]
19. Full-spectral genome analysis of natural killer/T cell lymphoma highlights impacts of genome instability in driving its progression.
Chen Z; Huang H; Hong H; Huang H; Weng H; Yu L; Xiao J; Wang Z; Fang X; Yao Y; Yue JX; Lin T
Genome Med; 2024 Apr; 16(1):48. PubMed ID: 38566223
[TBL] [Abstract][Full Text] [Related]
20. Expanding anti-CD38 immunotherapy for lymphoid malignancies.
Wang X; Yu X; Li W; Neeli P; Liu M; Li L; Zhang M; Fang X; Young KH; Li Y
J Exp Clin Cancer Res; 2022 Jun; 41(1):210. PubMed ID: 35765110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
